Zurcher Kantonalbank (Zurich Cantonalbank) Reata Pharmaceuticals Inc Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$79.22 - $105.37 $7,922 - $10,537	-100 Reduced 1.54%	6,397 $652,000
Q1 2023 May 08, 2023	BUY	$30.85 - $93.17 $37,667 - $113,760	1,221 Added 23.14%	6,497 $590,000
Q4 2022 Feb 01, 2023	BUY	$22.15 - $42.11 $17,520 - $33,309	791 Added 17.64%	5,276 $200,000
Q3 2022 Nov 09, 2022	SELL	$19.41 - $36.49 $388 - $729	-20 Reduced 0.44%	4,485 $113,000
Q2 2022 Aug 09, 2022	SELL	$20.71 - $36.5 $3,934 - $6,935	-190 Reduced 4.05%	4,505 $137,000
Q1 2022 Apr 21, 2022	SELL	$24.12 - $39.6 $458 - $752	-19 Reduced 0.4%	4,695 $154,000
Q4 2021 Feb 01, 2022	SELL	$25.61 - $110.96 $25 - $110	-1 Reduced 0.02%	4,714 $124,000
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $33,700 - $48,197	337 Added 7.7%	4,715 $474,000
Q2 2021 Jul 30, 2021	BUY	$78.27 - $151.29 $143,312 - $277,011	1,831 Added 71.89%	4,378 $620,000
Q1 2021 May 03, 2021	SELL	$94.25 - $132.81 $26,013 - $36,655	-276 Reduced 9.78%	2,547 $254,000
Q4 2020 Jan 28, 2021	BUY	$102.03 - $184.62 $24,793 - $44,862	243 Added 9.42%	2,823 $349,000
Q2 2020 Jul 28, 2020	BUY	$126.3 - $176.56 $104,450 - $146,015	827 Added 47.18%	2,580 $403,000
Q1 2020 May 06, 2020	BUY	$124.16 - $247.74 $52,147 - $104,050	420 Added 31.51%	1,753 $253,000
Q4 2019 Jan 21, 2020	BUY	$74.57 - $217.92 $6,935 - $20,266	93 Added 7.5%	1,333 $273,000
Q3 2019 Oct 18, 2019	BUY	$71.26 - $95.75 $17,743 - $23,841	249 Added 25.13%	1,240 $100,000
Q1 2019 Apr 29, 2019	BUY	$51.9 - $101.79 $25,742 - $50,487	496 Added 100.2%	991 $85,000
Q3 2018 Nov 09, 2018	BUY	$35.64 - $92.06 $17,641 - $45,569	495 New	495 $40,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account